Published 2 days ago • loading... • Updated 2 days ago

Girard Sharp LLP and Motley Rice LLC Announce Proposed Settlements in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC announced proposed settlements totaling $195 million in a class action involving Jazz Pharmaceuticals and Hikma Pharmaceuticals on May 28, 2025.
The lawsuit arose from allegations that Jazz, Hikma, Amneal, and Lupin delayed generic Xyrem availability and allocated the market, violating antitrust and consumer protection laws.
Jazz agrees to pay $145 million and Hikma $50 million, while the court previously approved $3.4 million settlements with Amneal and Lupin for related claims.
Claimants must submit their filings by October 3, 2025, to receive at least $15, and on October 23, 2025, the judge will review the proposed settlements along with requests for attorneys' fees amounting to as much as one-third of the settlement fund.
These settlements could compensate those who paid for Brand or Generic Xyrem, but claimants must exclude themselves by July 28, 2025, to retain rights to sue Jazz or Hikma.

Insights by Ground AI

Does this summary seem wrong?